论文部分内容阅读
支原体为临床引起原发性非典型性肺炎的一种重要病原体,晚近报告颇多,并有局部流行趋势。本病诊断长期依赖于血清抗体滴度测定及病原体分离培养等。但因存在耗时较久,检出阳性率颇低以及灵敏性和特异性欠佳等缺点,致使不能达到临床早期诊断的目的。晚近采用核酸分子杂交技术与传统聚合酶链反应(PCR)二者相结合的检测方法,使其特异性和灵敏性有了显著的提高。据此,作者检测上海市静安区中心医院1998年2月至6月,由急诊室收治临床存在明显呼吸道感染的85例患者,经核酸分子杂交技术确诊为支原体肺炎17例,检出阳性率为20％。本文的目的旨在探索该技术在诊断支原体肺炎之价值,以供临床选用。
Mycoplasma is a clinically important cause of SARS as an important causative agent, recently reported a lot, and there is a local trend. The diagnosis of the disease has long been dependent on serum antibody titers and pathogen isolation and culture. However, due to the existence of longer time, the detection of low positive rate and sensitivity and specificity of poor shortcomings, resulting in failure to achieve the purpose of early clinical diagnosis. Recent detection methods using a combination of nucleic acid hybridization and traditional polymerase chain reaction (PCR) have led to a significant increase in specificity and sensitivity. Accordingly, the author of Shanghai Jing’an District Central Hospital from February 1998 to June, admitted to the emergency room clinically significant respiratory infections in 85 patients, the nucleic acid molecular hybridization diagnosis of mycoplasma pneumonia in 17 cases, the positive rate was 20%. The purpose of this article is to explore the value of this technique in the diagnosis of mycoplasma pneumonia for clinical use.